Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.
作者信息
Canil Christina, Kapoor Anil, Basappa Naveen S, Bjarnason Georg, Bossé Dominick, Dudani Shaan, Graham Jeffrey, Gray Samantha, Hansen Aaron R, Heng Daniel Y C, Karakiewicz Pierre I, Kollmannsberger Christian, Lalani Aly-Khan A, North Scott A, Patenaude François, Soulières Denis, Thana Myuran, Winquist Eric, Wood Lori A, Reaume M Neil, Maloni Ranjena, Hotte Sebastien J
机构信息
Division of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, ON, Canada.
Division of Urology, McMaster University, Hamilton, ON, Canada.
出版信息
Can Urol Assoc J. 2021 Apr;15(4):84-97. doi: 10.5489/cuaj.7245.
Abstract
摘要
相似文献
1
Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021.晚期肾癌的管理：加拿大肾癌研究网络（KCRNC）2021年共识更新
Can Urol Assoc J. 2021 Apr;15(4):84-97. doi: 10.5489/cuaj.7245.
2
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.晚期肾癌的管理：加拿大肾癌研究网络（KCRNC）2019年共识更新
Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256.
3
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer.加拿大肾癌研究网络（KCRNC）关于肾肿物活检在肾癌管理中作用的共识声明。
Can Urol Assoc J. 2019 Dec;13(12):377-383. doi: 10.5489/cuaj.6176. Epub 2019 Sep 17.
4
Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.加拿大肾癌研究网络（KCRNC）关于减瘤性肾切除术对转移性肾细胞癌患者作用的共识声明。
Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786.
5
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.加拿大肾癌研究网络关于高危、非转移性肾细胞癌肾切除术后辅助治疗作用的共识声明：文献综合分析及随机对照试验的荟萃分析
Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.
6
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium.骨髓瘤表现与并发症的管理：支持性护理的基石：加拿大骨髓瘤研究小组（原加拿大骨髓瘤研究网络）共识指南联盟的建议
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e41-e56. doi: 10.1016/j.clml.2021.07.028. Epub 2021 Aug 1.
7
Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.晚期肾癌的管理：2013年加拿大肾癌论坛共识更新：2013年加拿大肾癌论坛
Can Urol Assoc J. 2013 Jul-Aug;7(7-8):238-43. doi: 10.5489/cuaj.536.
8
Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.晚期肾癌的管理：加拿大肾癌论坛共识更新
Can Urol Assoc J. 2015 May-Jun;9(5-6):164-70. doi: 10.5489/cuaj.2894.
9
Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.晚期肾癌的管理：2017年加拿大肾癌论坛（CKCF）共识更新
Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769.
10
CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update.CANVASC 共识推荐的抗中性粒细胞胞浆抗体相关性血管炎治疗建议：2020 更新版。
J Rheumatol. 2021 Apr;48(4):555-566. doi: 10.3899/jrheum.200721. Epub 2020 Sep 15.
引用本文的文献
1
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma.2024年美国泌尿外科学会-韩国肾脏研究与护理网络专家报告：非透明细胞肾细胞癌的管理
Can Urol Assoc J. 2024 Nov;18(11):E371-E386. doi: 10.5489/cuaj.9041.
2
Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.立体定向体部放射治疗在肾癌中的应用——原发性、减瘤性和寡转移性治疗情况综述
Cancers (Basel). 2024 Sep 29;16(19):3334. doi: 10.3390/cancers16193334.
3
Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review.寡转移和寡进展性肾细胞癌的局部治疗：叙述性综述。
Future Oncol. 2024;20(33):2573-2588. doi: 10.1080/14796694.2024.2389769. Epub 2024 Sep 11.
4
[Not Available].[无可用内容]
CMAJ. 2024 May 5;196(17):E601-E607. doi: 10.1503/cmaj.230356-f.
5
Advances in the management of renal cell carcinoma.肾细胞癌管理方面的进展
CMAJ. 2024 Feb 25;196(7):E235-E240. doi: 10.1503/cmaj.230356.
6
Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.免疫检查点抑制剂联合治疗晚期肾细胞癌的疗效和毒性：系统评价和网络荟萃分析。
Front Immunol. 2024 Feb 8;15:1255577. doi: 10.3389/fimmu.2024.1255577. eCollection 2024.
7
Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System.加拿大医疗体系中转移性肾细胞癌系统治疗的应用趋势。
JCO Glob Oncol. 2023 Sep;9:e2300271. doi: 10.1200/GO.23.00271.
8
Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.肾细胞癌辅助治疗：2023年加拿大肾癌论坛共识声明
Can Urol Assoc J. 2023 May;17(5):E154-E163. doi: 10.5489/cuaj.8381.
9
Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.晚期肾细胞癌治疗的下一波目标。
Curr Oncol. 2022 Jul 30;29(8):5426-5441. doi: 10.3390/curroncol29080429.
10
A Systematic Review and Meta-Analysis of Minimally Invasive Partial Nephrectomy Versus Focal Therapy for Small Renal Masses.微创部分肾切除术与小肾肿瘤聚焦治疗的系统评价和荟萃分析
Front Oncol. 2022 May 26;12:732714. doi: 10.3389/fonc.2022.732714. eCollection 2022.
本文引用的文献
1
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.立体定向放射治疗用于接受酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者的寡进展：一项2期前瞻性多中心研究
Eur Urol. 2021 Dec;80(6):693-700. doi: 10.1016/j.eururo.2021.07.026. Epub 2021 Aug 13.
2
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
3
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
4
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.舒尼替尼与卡博替尼、克唑替尼和索凡替尼治疗晚期乳头状肾细胞癌的比较：一项随机、开放标签、二期临床试验。
Lancet. 2021 Feb 20;397(10275):695-703. doi: 10.1016/S0140-6736(21)00152-5. Epub 2021 Feb 13.
5
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.派姆单抗联合阿昔替尼对比舒尼替尼作为晚期肾细胞癌的一线治疗（KEYNOTE-426）：一项随机、开放标签、III 期试验的延长随访。
Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.
6
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗晚期肾细胞癌：III期CheckMate 214试验的4年延长随访
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
7
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial.辅助索拉非尼治疗中高危复发风险肾细胞癌：来自 SORCE 随机 III 期多中心临床试验的结果。
J Clin Oncol. 2020 Dec 1;38(34):4064-4075. doi: 10.1200/JCO.20.01800. Epub 2020 Oct 14.
8
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.JAVELIN肾101试验的最新疗效结果：一线阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌患者的对比
Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25.
9
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019.晚期肾癌的管理：加拿大肾癌研究网络（KCRNC）2019年共识更新
Can Urol Assoc J. 2019 Oct;13(10):343-354. doi: 10.5489/cuaj.6256.
10
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.比较研究事后分析：晚期肾细胞癌帕唑帕尼应答者的特征。
Clin Genitourin Cancer. 2019 Dec;17(6):425-435.e4. doi: 10.1016/j.clgc.2019.01.015. Epub 2019 Feb 6.
Zotero 插件